Articles tagged with Drug Studies
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
The study demonstrated the potential of body-on-a-chip systems to transform the drug discovery process by accurately predicting cardiotoxic mechanisms and replicating in vivo results. The findings support the use of in vitro models to evaluate temporal pharmacokinetic/pharmacodynamic relationships.
Researchers from Mount Sinai highlight the importance of multidimensional data for stratifying a complex disease like asthma. Carefully designed, integrated multi-'omic' studies could accelerate precision medicine for asthma patients by defining asthma subtypes through transcriptomics and other omic approaches.
A new study found that one in five US adults experience harm because of someone else's drinking, with women more likely to report financial and family problems. Heavy drinking was linked to increased risk of harassment, threats, and driving-related harm.
A study of over 3,000 US counties found 412 high-risk areas with high opioid overdose mortality and low treatment capacity. Strategies to increase primary care clinician capacity and employment opportunities in these counties are recommended.
A review of 117 efforts to reduce low-value care found that most measured only the reduction of test and treatment use, while few assessed intended patient benefits or unintended consequences. Only half of ongoing studies aim to measure patient-reported outcomes, highlighting a need for more comprehensive evaluation.
Researchers found a consistent cholesterol-lowering effect for soy protein across all 46 trials, contradicting the FDA's proposed revocation of its health claim. The study's findings support the original FDA claim and highlight the benefits of incorporating soy into a plant-based diet.
A survey of orthopaedic providers found that they frequently recommend prescribing a nine-day supply of oxycodone after surgery, exceeding current guidelines. Despite knowledge gaps, the study highlights the need for evidence-based guidelines to curb overprescribing and patient harm.
The PHOENIx MDR-TB study compares the safety and efficacy of delamanid and isoniazid in preventing active MDR-TB disease in at-risk contacts. The trial will enroll approximately 5,610 participants across 12 countries.
Researchers at Lund University have made significant strides in developing a potential drug to combat preeclampsia, a life-threatening condition affecting millions of pregnant women worldwide. The study's findings confirm the therapeutic effects of alpha-1-microglobulin and suggest a promising path forward for patients with the disease.
A large multicentre randomised trial found no improvement in delivery rates with frozen embryo transfers compared to traditional fresh transfers. The study suggests that a general freeze-all strategy may not be beneficial for women with regular menstrual cycles.
Researchers call for long-term randomized deprescribing trials to explore whether reducing or eliminating anticholinergic medication use can improve cholinergic neurotransmission and reduce dementia risk. If successful, this approach could be a more feasible intervention than increasing physical activity or controlling diabetes.
A study published in JAMA Ophthalmology found that one-third of ophthalmic patients have discrepancies between clinician notes and EHR-generated medication lists. This inconsistency may lead to avoidable medication errors, threatening patient safety.
Researchers at Huntsman Cancer Institute discovered a new experimental drug, selinexor, which may block a crucial survival pathway exploited by myelofibrosis cells. A clinical trial has been designed to examine the drug's effectiveness in patients with myelofibrosis.
A new study found that even people with well-controlled epilepsy are at risk of sudden unexpected death in epilepsy (SUDEP). Researchers analyzed cases referred to the North American SUDEP Registry and found that sleep deprivation, skipping medication, and lack of seizure activity were common factors contributing to SUDEP.
A large-scale genetic study of diverse populations found that genetic mutations contributing to chronic diseases like diabetes vary across ethnicities. The research highlights the importance of including diverse populations in genetic studies to develop effective treatments for debilitating diseases.
A groundbreaking drug has shown significant growth benefits for children with achondroplasia, a genetic bone disorder affecting about one in every 25,000 infants. The four-year study found that the drug vosoritide increased height by up to 50% per year and was well-tolerated with no adverse effects on body proportion.
A four-year study found that vosoritide increased the average annual growth rate of children with achondroplasia by nearly 2 centimeters per year, bringing it close to average stature. The treatment also showed sustained effects and was generally well-tolerated.
A multicenter trial found that linagliptin reduced albuminuria but had no significant effect on eGFR or cardiovascular risk in patients with diabetes. The study also suggested that stratifying patients with nephrotic-range proteinuria could lead to better outcomes.
Researchers attach a removable lock to an arthritis drug to reduce systemic immune suppression and neutralization, making it safer and more effective. The modified form of the antibody shows promise in treating rheumatoid arthritis with fewer infections and less development of anti-infliximab antibodies.
Researchers tested a medication reservoir implant in 220 patients with wet age-related macular degeneration, finding it safe and effective in reducing the need for injections. The study showed significant improvements in eyesight, with patients able to see farther than before, and a longer time between refills.
A study analyzed medicine prices in Russia, finding a significant decrease since 2015, with generic prices nearing reference prices. Regulatory measures implemented in the Russian Federation have contributed to improving access to medicines.
The HOPE study demonstrates that low-dose prednisolone significantly improves pain symptoms and function in patients with painful hand osteoarthritis. The study found that prednisolone reduces synovitis and improves physical component scale and patient global assessment, making it a suitable target for treatment.
A systematic review found that serotonin and norepinephrine reuptake inhibitors (SNRIs) led to more harmful events compared to placebos in older adults. Antidepressants like SSRIs may increase the risk of falls, highlighting the need for careful consideration when prescribing these medications.
Researchers found that electronic inhaler monitoring, combined with a disease management program, reduced healthcare utilization in patients with COPD. The study showed a significant reduction in COPD-related hospitalizations and ER visits, from an average of 3.4 to 2.2 trips per year.
A team of UK scientists has identified the mechanism behind hardening of the arteries, which is associated with dementia, heart disease, high blood pressure, and stroke. They found that a generic medication normally used to treat acne could be an effective treatment for the condition.
A systematic review suggests that lithium's effects on breastfeeding are poorly understood due to sparse and poorly designed studies. Expert recommendations vary, and more research is necessary to inform patient decisions.
A clinical trial found that teplizumab, an immunotherapy drug, can delay the onset of type 1 diabetes in people at high risk. The study, published in the New England Journal of Medicine, showed a median delay of two years in children and adults.
Researchers review aspects of RA detection and intervention, highlighting potential for early screening and prevention. Studies discuss the development of effective preventive measures, which could significantly alter disease course and quality of life.
A randomized clinical trial found that patients taking IDegLira achieved and maintained lower blood glucose levels for longer periods compared to those taking insulin only. The study showed improved outcomes without the need for additional therapy, reducing side effects often associated with insulin-only treatment.
Researchers found that an immunotherapy treatment, teplizumab, effectively delayed the progression to clinical type 1 diabetes in high-risk individuals. Participants who received teplizumab took longer to develop clinical disease, with a median time of 48 months compared to just over 24 months for those in the control group.
A large international clinical trial found that dulaglutide reduced cardiovascular events by 12% and kidney disease by 15% in people with Type 2 diabetes. The study, REWIND, followed over 9,900 participants for five years.
A study of adults and youth with type 2 diabetes found that improvements in insulin release wane after treatment stops, highlighting the need for continued treatment. In contrast, youth experience more aggressive disease progression during and after treatment.
A large, multi-year randomized trial found no evidence to support claims that PPIs cause serious health issues such as pneumonia, chronic kidney disease, diabetes, and dementia. The study suggests that limiting prescriptions of PPI therapy is not appropriate due to the benefits outweighing the risks.
A new study found significant issues with non-medical use of alprazolam in the UK, particularly among younger adults. The estimated national prevalence of lifetime and recent use was 0.32% and 1.30%, respectively.
UC researchers present findings from the Belatacept Early Steroid Withdrawal Trial (BEST), showing that belatacept can safely and effectively treat kidney transplant patients. The study demonstrates reduced side effects and cardiovascular risk reduction compared to traditional immunosuppressive regimens.
A clinical trial found that galantamine reduced opioid positive urine samples and prolonged abstinence in participants. The medication's dual mechanism of action may offer new strategies for treating opioid use disorder.
The National Institutes of Health will fund clinical trials to assess genomic medicine interventions for managing diseases such as high blood pressure, depression, and chronic pain. The trials aim to improve treatment outcomes by tailoring drug prescriptions based on patients' genetic makeup.
A Phase II clinical trial conducted at MD Anderson Cancer Center revealed an 84.6% overall response rate and 38.5% complete response rate when combination targeted therapy was given prior to chemotherapy for newly diagnosed patients with a specific type of diffuse large B-cell lymphoma. The findings suggest that patients who respond to...
A new study has identified several potential approaches for improving medication adherence among Latinos with diabetes, including simple measures like pillboxes and family member education. The study also highlights specific challenges faced by underserved Latino communities, such as difficulty understanding medications and managing mu...
A study found that patients taking antihypertensive drugs had a decreased risk of developing dementia, with calcium channel blockers showing the most significant association. The study analyzed data from over 12,000 patients and suggested that these medications may help delay or reduce dementia onset.
The POLO trial shows that olaparib significantly reduces the risk of disease progression or death in metastatic pancreatic cancer patients with BRCA mutations. Progression-free survival was 7.4 months on the olaparib arm, compared to 3.8 months on the placebo arm.
Researchers at Fred Hutchinson Cancer Center have successfully treated cancer patients with HIV using immunotherapy drug pembrolizumab. The study found that the drug was safe and effective in patients with well-controlled HIV, offering hope for inclusivity in future clinical trials.
The NCI-MATCH trial found a combination of dabrafenib and trametinib to be effective in treating patients with BRAF mutations across 17 distinct tumor types, including several rare cancer types. The treatment showed promising activity outside of currently approved FDA indications.
A large study has demonstrated that enzalutamide improves outcomes for men with metastatic hormone-sensitive prostate cancer, with an overall survival rate of 80% after three years. This new treatment option is especially relevant for men who cannot tolerate chemotherapy and have a lower burden of disease.
Researchers developed COXEN, a predictive tool that analyzes gene expression to predict response to chemotherapy in bladder cancer patients. The trial showed COXEN's ability to predict response using Gemcitabine-Cisplatin (GC) biomarker.
Researchers suggest that cannabinoids may relieve symptoms of OCD and related disorders through targeting the endocannabinoid system. Animal study data and preliminary human clinical trial results support continued pharmaceutical development.
A virtual clinical trial using real-world data found entrectinib to be more effective than crizotinib in treating ROS1+ lung cancer. Patients on entrectinib stayed on treatment longer and had a 44% increased chance of cancer recurrence compared to those on crizotinib.
A study from Joslin Diabetes Center found that removing senescent beta-cells can recover their function and improve glucose metabolism in mice with insulin resistance. The researchers hope to develop a potential treatment using senolytics, which target aging cells contributing to disease dysfunction.
A new study presented at ASCO 2019 shows that brigatinib is effective in patients who have received another next-generation ALK inhibitor. The 40-50 percent response rate suggests that brigatinib may be a useful treatment option for these patients. Detailed molecular analyses will help determine the characteristics of patients sensitiv...
A recent study published in Psychopharmacology found that MDMA-assisted psychotherapy significantly improved PTSD symptoms, with 54% of participants no longer meeting criteria after two sessions. The therapy was compared to small doses or non-drug psychotherapy and showed promising results.
A new study suggests that 7-hydroxymitragynine, a kratom metabolite, is responsible for the treatment's therapeutic effects. The researchers found that most of the analgesic effect comes from this compound rather than mitragynine.
A national survey found hundreds of young carers struggling to keep up with studies due to unpredictable family responsibilities. Experts call for tailored programs to improve engagement and future outcomes.
Researchers aim to determine if stopping anticholinergic medications improves cognition and potentially delays or prevents dementia. The 'Reducing Risk of Dementia through Deprescribing' study will enroll 344 older adults and monitor the impact on cognitive function over 2 years.
A study of 20,000 patients found that reading their clinicians' visit notes significantly improves patient-reported behaviors and perceptions concerning benefits versus risks. Patients reported increased understanding of medications and felt more in control of their medications after reading their notes.
Patients with stable chronic heart failure can safely discontinue diuretics without increased dyspnoea or reuse of the medication. The ReBIC-1 trial found no significant differences in symptom relief between patients who stopped and those who continued taking furosemide.
A new nerve stimulation therapy may provide a new treatment option for the most common type of stroke. The study found that this active nerve cell cluster stimulation reduced patients' degree of disability three months after they suffered an acute cortical ischemic stroke.
A new study from the University of Cambridge suggests that virtual reality can spot navigation problems in early Alzheimer's disease, a condition affecting over 525,000 people in the UK. The research highlights the potential of new technologies to help diagnose and monitor conditions like Alzheimer's.
Researchers tracked outcomes from 537 people with brain haemorrhage while taking antiplatelet medicines, finding fewer recurrences compared to those who didn't take these treatments. The study suggests treatments may reduce rather than increase risk of further bleeding in the brain.
SWOG researchers present numerous high-impact trials at ASCO, focusing on symptom control, survivorship, and quality of care. Studies explore the effectiveness of text messaging for medication adherence in breast cancer patients and investigate gender disparities in severe adverse events among chemotherapy recipients.
A recent study found that children with cancer wait an average of 6.5 years longer than adults to access new drugs. Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center are advocating for improved pediatric trial timelines. The delay can lead to a lack of effective treatments for life-threatening diseases.